aspart insulin + lipro insulin-Nanjing First Hospital, Nanjing Medical University-type 2 diabetes mellitus

This entry refers to a Phase 4 clinical trial (NCT02363829) conducted by Nanjing First Hospital and Nanjing Medical University comparing two rapid-acting insulin analogues: insulin aspart (NovoRapid) and insulin lispro (Prandilin). The study evaluated the efficacy and safety of these insulins when administered via continuous subcutaneous insulin infusion (CSII) in combination with metformin for newly diagnosed type 2 diabetes mellitus patients with high HbA1c levels (>9%). Both insulin aspart and insulin lispro are biologics that function as agonists of the insulin receptor, facilitating glucose uptake and regulating blood sugar levels. The trial utilized continuous glucose monitoring (CGM) to assess glycemic variability between the two treatment arms.

Brand names

NovoRapidPrandilin

Other names

insulin aspartinsulin lisproinsulin lipro